Quoth The Financial Times, in an extraordinarily-candid, wide-ranging interview -- with the CEO of Sanofi-Aventis -- thus:
. . . .He said a decision would be made during the first quarter of next year on whether to make fresh investments to combine Meriel – the animal health joint venture it runs with Merck of the US – with the extra products Merck has acquired in its recent take-over of Schering-Plough. . . .
So by then, it will have been going on for three solid years [since early 2007, when rumors first surfaced of an Intervet sell-off to old (legacy) Schering-Plough], that the legacy Organon-Intervet workforce will have been "living in limbo" -- not knowing who will own it, who they'll work for, or whether they will have ongoing, long-term work prospects, at all.